Olusola Olawoye1,2, Adelina A Ashaye1,2, Tarela F Sarimiye1,2. 1. Department of Ophthalmology, University of Ibadan College of Medicine, Ibadan, Oyo, Nigeria. 2. Department of Ophthalmology, University College Hospital, Ibadan, Oyo, Nigeria.
Abstract
AIM: To report the safety and efficacy of Argon Laser Trabeculoplasty (ALT) in reducing intraocular pressure (IOP). SETTINGS AND DESIGN: This was a retrospective study performed on 25 eyes of 25 patients. METHODS AND MATERIALS: Consecutive patients who met the inclusion criteria for ALT were recruited from the ophthalmic clinic of the University College Hospital Ibadan, Nigeria and followed up for a minimum period of six months. Two criteria were used to define successful response. Criterion 1 was defined as IOP reduction of 3mmHg or more without additional intervention while criterion 2 was IOP reduction of 20% or more from the pretreatment IOP. STATISTICAL ANALYSIS: Data was analyzed using SPSS version 16. Frequencies and means were generated to observe patterns of variable distribution among the patients. P value < 0.05 was considered significant. RESULTS: The mean pretreatment IOP was 19.9 ±3.1mmHg, (range of 16 to 26 mmHg). Mean post treatment IOP at 6 months was 14.9 ±2.2 mmHg, (range of 11 to 19 mmHg). Mean IOP reduction at one year was 4.6 mmHg, representing a 22.3% drop. There was a statistically significant greater IOP reduction in eyes (P<0.001) with higher pretreatment IOP. Based on criterion 1 and 2, 84.0% of the patients had successful outcome at six months while at one year, 76.9% were successful based on criterion one. CONCLUSION: To the best of our knowledge, this is the first study to report the efficacy of ALT in Nigerians. ALT is safe and effective in reducing IOP in Nigerians. KEY MESSAGES: ALT is safe and effective in reducing intraocular pressure in this population of Nigerians. FUNDING: The present study did not receive any funds.
AIM: To report the safety and efficacy of Argon Laser Trabeculoplasty (ALT) in reducing intraocular pressure (IOP). SETTINGS AND DESIGN: This was a retrospective study performed on 25 eyes of 25 patients. METHODS AND MATERIALS: Consecutive patients who met the inclusion criteria for ALT were recruited from the ophthalmic clinic of the University College Hospital Ibadan, Nigeria and followed up for a minimum period of six months. Two criteria were used to define successful response. Criterion 1 was defined as IOP reduction of 3mmHg or more without additional intervention while criterion 2 was IOP reduction of 20% or more from the pretreatment IOP. STATISTICAL ANALYSIS: Data was analyzed using SPSS version 16. Frequencies and means were generated to observe patterns of variable distribution among the patients. P value < 0.05 was considered significant. RESULTS: The mean pretreatment IOP was 19.9 ±3.1mmHg, (range of 16 to 26 mmHg). Mean post treatment IOP at 6 months was 14.9 ±2.2 mmHg, (range of 11 to 19 mmHg). Mean IOP reduction at one year was 4.6 mmHg, representing a 22.3% drop. There was a statistically significant greater IOP reduction in eyes (P<0.001) with higher pretreatment IOP. Based on criterion 1 and 2, 84.0% of the patients had successful outcome at six months while at one year, 76.9% were successful based on criterion one. CONCLUSION: To the best of our knowledge, this is the first study to report the efficacy of ALT in Nigerians. ALT is safe and effective in reducing IOP in Nigerians. KEY MESSAGES: ALT is safe and effective in reducing intraocular pressure in this population of Nigerians. FUNDING: The present study did not receive any funds.
Authors: Hung Pham; Steven Mansberger; James D Brandt; Karim Damji; Pradeep Y Ramulu; Richard K Parrish Journal: Surv Ophthalmol Date: 2008 Nov-Dec Impact factor: 6.048
Authors: Mark S Juzych; Vikás Chopra; Michael R Banitt; Bret A Hughes; Chaesik Kim; Mark T Goulas; Dong H Shin Journal: Ophthalmology Date: 2004-10 Impact factor: 12.079
Authors: Fatima Kyari; Murthy V S Gudlavalleti; Selvaraj Sivsubramaniam; Clare E Gilbert; Mohammed M Abdull; Gabriel Entekume; Allen Foster Journal: Invest Ophthalmol Vis Sci Date: 2008-12-30 Impact factor: 4.799